Hypercholesterolaemia treated with inclisiran.

Q4 Medicine Ugeskrift for laeger Pub Date : 2024-06-10 DOI:10.61409/V12230767
Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert
{"title":"Hypercholesterolaemia treated with inclisiran.","authors":"Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert","doi":"10.61409/V12230767","DOIUrl":null,"url":null,"abstract":"<p><p>In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.</p>","PeriodicalId":23428,"journal":{"name":"Ugeskrift for laeger","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ugeskrift for laeger","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61409/V12230767","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用 inclisiran 治疗高胆固醇血症。
在这份病例报告中,一名 31 岁的杂合子家族性高胆固醇血症(FH)女性患者接受了他汀类药物和 PCSK9 抑制剂治疗,但由于肌酸激酶水平升高以及神经和肌肉副作用而不得不停止治疗。2021 年,该患者接受了 inclisiran 治疗,这是丹麦首次应用该疗法。治疗过程中未出现任何副作用,低密度脂蛋白胆固醇水平显著降低。本病例报告强调了 inclisiran 作为一种有效且耐受性良好的治疗方法对杂合性 FH 患者的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ugeskrift for laeger
Ugeskrift for laeger Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
345
期刊介绍: The Ulster Medical Journal is an international general medical journal with contributions on all areas of medical and surgical specialties relevant to a general medical readership. It retains a focus on material relevant to the health of the Northern Ireland population. The Honorary Editor would welcome offers of papers for publication. Prospective authors are invited to read the notice to contributors.
期刊最新文献
Ictal asystole is a rare complication of epilepsy. Intravenous iron preoperatively for woman with severe anaemia. Pneumoperitoneum ved perforeret miltabsces. Posterior reversible encephalopathy syndrome. Social-motional challenges in children of mothers with postpartum depression.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1